Biotechnology

enVVeno Medical to Present at the Ladenburg Thalmann 2022 Healthcare Conference

September 22, 2022 8:05 AM

Live video webcast fireside chat on Thursday, September 29th at 2:00 PM ET IRVINE, CA / ACCESSWIRE / September 22, 2022 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, today announced that Rob Berman, Chief Executive Officer of enVVeno Medical, will participate in a fireside chat at the Ladenburg Thalmann 2022 Healthcare Conference being held...

Read more

Ensysce Biosciences Announces Initiation of Second Human Abuse Potential Study, Being Conducted by DVCR

September 22, 2022 8:05 AM

~ Oral Opioid Abuse Being Explored for PF614 ~ ~ Data From Trial Supports Abuse Deterrent Labeling, Designed to Measure the Potential for Drug Liking ~ SAN DIEGO, CA / ACCESSWIRE / September 22, 2022 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC)(OTC PINK:ENSCW), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety focused on reducing abuse and overdose, today announced...

Read more

Aqualung Therapeutics Corp. Awarded $4.8M Dollars From National Institute of Health (NIH) To Develop the ALT-100 Monoclonal Antibody for Pulmonary Arterial Hypertension and Inflammatory Bowel Disease

September 21, 2022 6:30 PM

TUCSON, AZ / ACCESSWIRE / September 21, 2022 / Aqualung Therapeutics, an immunotherapeutics biotech company with an anti-inflammatory and anti-fibrosis therapeutic platform for serious unchecked inflammatory and fibrotic disorders, has been awarded two 3-year NIH FAST-TRACK AWARDS [R42DK135208; R42HL160422) to support development of ALT-100, a humanized monoclonal antibody (mAb) therapy for the chronic indications of Pulmonary Arterial...

Read more

enVVeno Medical Announces the Development of a Transcatheter Based Replacement Venous Valve for the Treatment of Chronic Venous Insufficiency

September 21, 2022 4:01 PM

Potential relief to approximately 3.5 million CVI sufferers Designed to be used by an expansive network of physicians Initial bench testing and animal testing successfully completed Awaiting regulatory approval to begin first-in-human testing, which is expected by end of 2022 Company to host conference call with live audio webcast today, Wednesday, September 21st at 4:30 PM ET IRVINE, CA / ACCESSWIRE / September 21, 2022 / enVVeno Medical...

Read more

Media Alert: BrainChip Chief Development Officer Presents at tinyML Neuromorphic Engineering Forum

September 21, 2022 9:00 AM

LAGUNA HILLS, CA / ACCESSWIRE / September 21, 2022 / Anil Mankar, Chief Development Officer at BrainChip Holdings Ltd (ASX:BRN)(OTCQX:BRCHF)(ADR:BCHPY), the world's first commercial producer of ultra-low power neuromorphic AI IP, will present "Combining Neuromorphic Design Principles with Modern Machine Learning Algorithms" at tinyML Neuromorphic Engineering Forum at 10:55 a.m. PDT September 27. Mr. Mankar's presentation will discuss how...

Read more

Sonnet BioTherapeutics Announces Progress in Two Phase 1 Dose-Escalation Trials of SON-1010

September 21, 2022 8:00 AM

The SB101 and SB102 studies have together dosed 19 subjects to date This early review of safety sets the stage for further dose escalation Additional safety and cytokine-specific data are expected during the fourth calendar quarter of 2022 PRINCETON, NJ / ACCESSWIRE / September 21, 2022 / Sonnet BioTherapeutics Holdings, Inc., (NASDAQ:SONN) a clinical-stage company developing targeted immunotherapeutic drugs, announced today that initial safety...

Read more

enVVeno Medical to Host Conference Call and Webcast on September 21, 2022

September 19, 2022 8:05 AM

- Conference call with live audio webcast to be held on Wednesday, September 21st at 4:30 PM ET IRVINE, CA / ACCESSWIRE / September 19, 2022 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, today announced it will host a conference call and webcast on Wednesday, September 21, 2022 at 4:30 PM ET. Interested participants and investors may access...

Read more

Enzolytics Inc. Announces Collaboration with Abveris to Discover Monoclonal Antibodies

September 16, 2022 6:30 AM

COLLEGE STATION, TX / ACCESSWIRE / September 16, 2022 / Enzolytics, Inc. (OTC Markets "ENZC" or the "Company"). Enzolytics, Inc. announces a collaboration with Abveris, a division of Twist Bioscience Corporation, to discover fully human monoclonal antibodies against multiple viruses. Abveris applies advanced immunization methods combined with B cell screening and hybridoma-based antibody discovery technologies to provide comprehensive...

Read more

CAGE Bio, TAGCyx, and PeptiStar Announce Execution of a License Agreement for Development and Commercialization of TAGX-0003 for the Treatment of Immunodermatology Diseases Mediated by the IFN-Gamma Pathway

September 15, 2022 3:00 PM

SAN CARLOS, CA and FORT WORTH, TX / ACCESSWIRE / September 15, 2022 / CAGE Bio Inc. (hereinafter "CAGE Bio"), a biotechnology company focused on developing innovative therapies for infection, inflammation and immunology and TAGCyx Biotechnologies Inc. (hereinafter "TAGCyx"), a biotechnology company developing DNA aptamer drugs based on its proprietary artificial nucleic acid base pair technology, announce the execution of a license agreement for...

Read more

Aqualung Therapeutics Receives the AZ-Bio Fast Lane Award and Achieves Key FDA-Related Milestones

September 13, 2022 10:50 AM

TUCSON, AZ / ACCESSWIRE / September 13th, 2022 / Aqualung Therapeutics, an immunotherapeutics biotech company with an anti-inflammatory therapeutic platform for serious unchecked inflammatory disorders, announced the achievement of two key FDA milestones for their therapeutic mAb ALT-100. First is the successful FDA IND submission for the indication of Acute Respiratory Distress Syndrome (ARDS). Second is the scheduling of an FDA Pre-IND type B...

Read more

Nascent Biotech Completes Fourth Cohort in Phase 1 Human Trial for Primary and Metastatic Brain Cancer

September 13, 2022 8:00 AM

VERO BEACH, FL / ACCESSWIRE / September 13, 2022 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology Company pioneering the development of monoclonal antibodies targeting various cancer types, announced today the completion of the Fourth Cohort in dosing patients in the Company's Phase I trial to evaluate Pritumumab ("PTB") as a treatment for Brain Cancer, including Primary and...

Read more

enVVeno Medical to Present at the H.C. Wainwright 24th Annual Global Investment Conference

September 12, 2022 7:00 AM

IRVINE, CA / ACCESSWIRE / September 12, 2022 / enVVeno Medical Corporation (Nasdaq:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, today announced that Robert Berman, CEO of enVVeno, will present at the H.C. Wainwright 24th Annual Global Investment Conference being held in New York, NY and virtually on September 12-14, 2022. In addition to the presentation, management will be...

Read more

Edesa Biotech to Present at Upcoming H.C. Wainwright Investor Conference

September 8, 2022 4:30 PM

TORONTO, ON / ACCESSWIRE / September 8, 2022 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, announced today that Par Nijhawan, MD, Chief Executive Officer, will present at the H.C. Wainwright Global Investment Conference being held in New York, NY on September 12-14, 2022. Edesa Presentation Details Date: September 12, 2022 Time: 10:00 am Eastern Time...

Read more

Ensysce Biosciences Announces Results of Special Meeting of Stockholders

September 8, 2022 4:15 PM

SAN DIEGO, CA / ACCESSWIRE / September 8, 2022 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC)(OTC PINK:ENSCW), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety to reduce abuse and overdose, today announced the results of the special meeting of stockholders held September 8, 2022. This meeting was held virtually, and the following resolutions were submitted and adopted...

Read more

Pieris Pharmaceuticals to Present at H.C. Wainwright 24th Annual Global Investment Conference

September 8, 2022 4:01 PM

BOSTON, MA / ACCESSWIRE / September 8, 2022 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer and other indications, today announced that management is scheduled to present at the H.C. Wainwright 24th Annual Global Investment Conference on Wednesday, September 14, 2022 at 12:30 PM EDT. A...

Read more

Internationally Published, Head-to-Head Data From India of Petros Pharmaceuticals' STENDRA(R) (Avanafil) Tablets Reported Improvement in Erectile Function Compared to Sildenafil and Baseline After 12 Weeks of Therapy

September 8, 2022 9:00 AM

Data Published in the "International Journal of Urology" Also Showed Secondary Endpoints, Such as Onset of action in 15 Minutes and Percentage of Patients Reaching Normal Erectile Function According to the IIEF-EF Score NEW YORK, NY / ACCESSWIRE / September 8, 2022 / Petros Pharmaceuticals, Inc. (NASDAQ:PTPI), a leading provider of therapeutics for men's health, today announces newly published third party data in the International Journal of...

Read more

Media Alert: BrainChip Presents at Edge AI Summit and AI Hardware Summit

September 8, 2022 9:00 AM

LAGUNA HILLS, CA / ACCESSWIRE / September 8, 2022 / BrainChip Holdings Ltd (ASX:BRN)(OTCQX:BRCHF)(ADR:BCHPY), the world's first commercial producer of ultra-low power neuromorphic AI IP, is exhibiting at both Edge AI Summit and AI Hardware Summit, which are being held concurrently at the Santa Clara Marriott in Santa Clara, Calif., September 13-15. BrainChip will be demonstrating its Akida technology live during both events with company...

Read more

Xenetic Biosciences, Inc. to Present at the H.C. Wainwright 24th Annual Global Investment Conference

September 7, 2022 8:05 AM

FRAMINGHAM, MA / ACCESSWIRE / September 7, 2022 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies for the treatment of hard to treat cancers, today announced that Jeffrey F. Eisenberg, Chief Executive Officer of Xenetic will present at the H.C. Wainwright 24th Annual Global Investment Conference being held in New York, NY and virtually...

Read more

Edesa Biotech Reports Phase 2b Study Reaches Full Enrollment

September 7, 2022 8:00 AM

Primary Endpoint To Be Reached Within 30 Days, With Topline Data Available by End of Year Company Evaluating Partnership and Out-Licensing Opportunities Outside North America for Its First-in-Class, Anti-Inflammatory Drug Candidate TORONTO, ON / ACCESSWIRE / September 7, 2022 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today announced that patient...

Read more

Chris Stevens, Industry Veteran Joins BrainChip to Lead Worldwide Sales

September 6, 2022 9:00 AM

LAGUNA HILLS, CA / ACCESSWIRE / September 6, 2022 / BrainChip Holdings Ltd (ASX:BRN)(OTCQX:BRCHF)(ADR:BCHPY), the world's first commercial producer of neuromorphic AI IP, announced that Chris Stevens has joined as Vice President of Worldwide Sales to lead and expand BrainChip sales. Mr. Stevens will leverage his extensive sales leadership experience and semiconductor network to drive customer opportunity and revenue. Mr. Stevens was most...

Read more